Healthcare - Biotechnology - NASDAQ - US
$ 8.5
-3.74 %
$ 600 M
Market Cap
-4.83
P/E
CASH FLOW STATEMENT
-85.7 M
OPERATING CASH FLOW
-43.4 M
INVESTING CASH FLOW
85.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ORIC Pharmaceuticals, Inc.
| Net Income | -101 M |
| Depreciation & Amortization | 1.03 M |
| Capital Expenditures | -849 K |
| Stock-Based Compensation | 15.2 M |
| Change in Working Capital | 4.9 M |
| Others | -4.53 M |
| Free Cash Flow | -86.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (100.7) | (89.1) | (78.7) | (73.7) | (26.9) | (21.4) | (22.0) |
| Depreciation & Amortization | 1.0 | 1.0 | 0.9 | 1.0 | 1.0 | 0.9 | 0.9 |
| Deferred Income Tax | 0 | 0 | 0 | 0.3 | 0 | 0 | 0 |
| Stock Based Compensation | 15.2 | 14.5 | 12.9 | 5.3 | 1.1 | 0.5 | 217 |
| Other Operating Activities | (6.1) | (1.0) | 1.4 | 19.8 | 8 K | 15 K | 2.0 |
| Change in Working Capital | 4.9 | (0.4) | 4.1 | 2.0 | 1.2 | (0.7) | 95 K |
| Cash From Operations | (85.7) | (75.1) | (59.5) | (45.3) | (23.5) | (20.7) | (20.8) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.8) | (2.1) | (0.9) | (0.7) | (0.8) | (0.5) | (0.5) |
| Other Items | (42.6) | (107.2) | 159.4 | (215.3) | 0 | 17 K | 0.2 |
| Cash From Investing Activities | (43.4) | (109.2) | 158.4 | (216.0) | (0.8) | (0.5) | (0.3) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.7 | 0.2 | (0.9) | (20.8) | 70.8 | 38.0 | 0 |
| Cash From Financing Activities | 85.7 | 25.6 | 49.1 | 250.5 | 70.8 | 38.0 | 0.3 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (43.4) | (159.2) | 148.0 | (10.7) | 46.5 | 16.8 | (20.9) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (86.5) | (77.2) | (60.5) | (45.9) | (24.3) | (21.2) | (21.3) |